fda declaratory order semaglutide shortage resolved feb 21 2025 ends as sets deadline for compounders fda semaglutide shortage resolved feb

For instance, other GLP-1 receptor agonists may have a different impact on gastric emptying or be associated with a lower incidence of heartburn

Medullary thyroid cancer Gallbladder issues Anaphylaxis (severe allergic reaction) Seek immediate medical attention if you experience any severe symptoms on a GLP-1 or other medication

DPP-4 inhibitors (such as sitagliptin or linagliptin) provide a well-tolerated oral option with a low risk of hypoglycaemia, though their glucose-lowering efficacy is generally more modest than GLP-1 receptor agonists

Note: You may only switch Rybelsus formulations if youre currently taking a maintenance dose of Rybelsus

This is a fundamental difference that directly affects both your safety and your results